Navigation Links
Filing Yaz Class Action Lawsuits Before They Expire
Date:7/18/2012

HOUSTON, July 18, 2012 /PRNewswire/ -- The attorneys at Pulaski & Middleman, LLC are actively representing women affected by the adverse side effects of the birth control drugs Yaz and Yasmin and the maker of the drugs, Bayer Pharmaceuticals. Medical malpractice lawyers are committed to protecting the legal rights of women who have been misinformed of the risks of taking these drugs.  The cutoff date for filing has not yet been determined, but the current Class Action Settlement will likely close within a year or less. Since the timeframe is unclear, it is highly recommended that women take action and file their suits now.

Bayer Pharmaceuticals recently indicated which types of cases it would agree to settle as well as what the average amount would be. More than 10,000 individuals have filed a Yaz lawsuit. The formal class action lawsuit is known as Yasmin and Yaz (Drospirenone) Marketing, Sales Practices and Products Liability Litigation.

The most common lawsuits that have been filed are by women have suffered stroke, Deep Vein Thrombosis (DVP) or Pulmonary Embolism after taking Yaz. Recent studies have linked drospirenone, the chemical present in the birth control drugs, to blood clots that can cause these conditions to occur. The FDA recently released a study, which followed more than 825,000 women taking oral contraceptives and found that women taking Yaz face up to a 74% increased risk of developing blood clots, DVT and pulmonary embolism.

The law office of Pulaski & Middleman, LLC urges women who have experienced these life-threatening injuries to contact an experienced personal injury lawyer and investigate your rights now. The window of time to claim your injury is small as it took Bayer Pharmaceuticals 4 years to open up the settlements.

Contact the experienced Yaz attorneys at Pulaski & Middleman, LLC today if you or a loved one has experienced the harmful effects of the birth control drug. Contact toll free at 1-800-BAD-DRUG.


'/>"/>
SOURCE Pulaski & Middleman, LLC
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. CSL Behring Announces FDA Filing of Biologics License Application for 4-Factor PCC for Urgent Reversal of Vitamin K Antagonist Anticoagulant Therapy
2. Depomed Announces Filing Of Shelf Registration To Replace Existing Shelf
3. ESTEVE Announces Publication of Key Preclinical Data for a Novel Oral, First-in-class New Chemical Entity (NCE) Sigma-1 Receptor Antagonist (E-52862), that has Completed Phase I and Initiated its Phase II Clinical Trial Program
4. Attorneys for Class of Female VPs and SVPs Employed by PR Giant MSLGroup Clarify Companys Inaccurate Description of Federal Courts Recent Certification Ruling
5. MAQUET Initiates Class I Recall of the FLOW-i Anesthesia System
6. Sanford Wittels & Heisler Files $100 Million Gender Discrimination Class Action In Southern District Of New York
7. Boston Scientific Completes Patient Enrollment in PREVAIL Study for First-in-Class WATCHMAN Device
8. Frost & Sullivan: Launch of New Classes of Oral Antidiabetic Drugs by 2014 will Uplift Prospects for the European Diabetes Therapeutics Market
9. Faruqi & Faruqi, LLP Notifies Investors of June 4, 2012 Lead Plaintiff Deadline for the Class Action Filed Against Chelsea Therapeutics International
10. Study of First-in-Class WATCHMAN® Device Shows 75 Percent Reduction in Stroke Risk in Patients with Atrial Fibrillation Not Eligible for Oral Anticoagulation Therapy
11. eCardios CEO to Speak During "Act at the Speed of Opportunity" Event Presented by Comcast Business Class and Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 24, 2016  Arkis BioSciences, a leading innovator ... more durable cerebrospinal fluid treatments, today announced it ... funding is led by Innova Memphis, followed by ... private investors.  Arkis, new financing will accelerate the ... market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Dialysis Devices Global Market - Forecast to 2022" report ... is the treatment method for the patients with kidney failure, ... and excess fluid from the patient,s blood and thus the ... sodium, potassium and chloride in balance. Increasing ...
(Date:6/23/2016)... 23, 2016 Research and Markets ... Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic ... Coating, Parenteral) - Global Forecast to 2021" report ... The global pharmaceutical excipients market is projected to ... of 6.1% in the forecast period 2016 to 2021. ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating in cancer care, and ... in the eye of the beholder, according to experts who offered insights and commentary ... of Managed Care. For the full issue, click here . , For the ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many women are ... with endometriosis. These women need a treatment plan to not only alleviate symptoms ... can help for preservation of fertility and ultimately achieving a pregnancy. The specialists ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , the largest ... as the Medical Director of its new Mesquite-Samuell Farm facility. , “We are ... Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published ... unfamiliar with. The article goes on to state that individuals are now more comfortable ... less common operations such as calf and cheek reduction. The Los Angeles area medical ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced that ... chosen by their peers for this recognition are considered among the top 2 percent ... special honors as members of this year’s Legal Elite Hall of Fame: Miami ...
Breaking Medicine News(10 mins):